Drug intelligence / Profile preview

Kaprolac

Development stage: Phase 3
Lead developer: Moberg Pharma
Modality: Small Molecules
Administration: Topical

Overview

Kaprolac is a range of medical products developed by Moberg Pharma AB (formerly Moberg Derma) for the treatment of scalp and skin disorders. One specific product within this range, Kaprolac K301, is a liquid formulation being investigated in a Phase III clinical trial for the treatment of mild to moderate seborrhoeic eczema (SE) of the scalp. K301 is applied topically once daily and aims to improve symptoms such as erythema and desquamation.

Brand names: Kaprolac

Targets

PTGS2 (Prostaglandin-Endoperoxide Synthase 2)PGHS-1 (Prostaglandin G/H Synthase 1)

Beyond the preview

Go deeper on Kaprolac.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Kaprolac.

Explore the full profile